Abbott Laboratories Stock Forecast for 2023 - 2025 - 2030
Updated on 04/25/2024
Abbott Laboratories Stock Forecast and Price Target
Abbott Laboratories's stock price reaches the average target of $126.50 by 2025 as expected recently by seven notable experts, there would be a potential upside of approximately 18.38% from the last closing price in April, 2024. This possible increase is based on a high estimate of $143.00 and a low estimate of $104.00. If you are interested in ABT stock, it is important to also consider its competitors.
18.38% Upside
Abbott Laboratories Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Abbott Laboratories's Price has decreased from $82.27 to $0.00 – a 100.00% drop. For next year, analysts predict Fair Value of $124.65, which would mean an increase of 100.00%. Over the next seven years, experts predict that Abbott Laboratories's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$724.87 | Buy/Sell | $636.99 | 15.54% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£120.26 | Buy/Sell | £165.99 | 34.72% |
| DHR Stock Forecast | Danaher | Outperform |
10
|
$245.80 | Buy/Sell | $260.33 | 9.85% |
| AMAT Stock Forecast | Applied Materials Inc | Outperform |
8
|
$197.50 | Buy/Sell | $168.54 | 13.92% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$269.38 | Buy/Sell | $303.65 | 17.77% |
Abbott Laboratories Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's Revenue has grown by 15.90%, rising from $34.61B to $40.11B. For next year, analysts predict Revenue of $44.20B, which would mean an increase of 10.20%. Over the next seven years, experts predict that Abbott Laboratories's Revenue will grow at a rate of 27.68%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BSX Stock Forecast | Boston Scientific | Outperform |
11
|
$73.26 | Buy/Sell | $70.14 | 9.20% |
| CSL Stock Forecast | CSL | Outperform |
12
|
$278.45 | Buy/Sell | $205.51 | -27.04% |
| CL Stock Forecast | Colgate-Palmolive Co | Outperform |
18
|
$89.29 | Buy/Sell | $88.97 | 4.16% |
.jpg)
Abbott Laboratories Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's Dividend per Share has grown, rising from $1.53 to $2.08 – a growth of 35.95%. In the next year, analysts believe that Dividend per Share will reach $2.11 – an increase of 1.44%. For the next seven years, the forecast is for Dividend per Share to grow by 24.33%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$230.48 | Buy/Sell | $284.47 | 21.49% |
| DXCM Stock Forecast | DexCom Inc | Buy |
12
|
$138.01 | Buy/Sell | $125.98 | 8.69% |
| EW Stock Forecast | Edwards Lifesciences Corp | Outperform |
11
|
$88.01 | Buy/Sell | $91.18 | 10.21% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MMM Stock Forecast | 3M | Hold |
10
|
$91.41 | Buy/Sell | $109.39 | 9.40% |
| BN Stock Forecast | Danone | Outperform |
11
|
59.30€ | Buy/Sell | 55.47€ | 7.93% |
| A Stock Forecast | Agilent Technologies | Outperform |
10
|
$136.37 | Buy/Sell | $138.82 | 11.09% |
Abbott Laboratories EBITDA Forecast for 2023 - 2025 - 2030
Abbott Laboratories's EBITDA has seen impressive growth In the last three years, rising from $8.99B to $10.46B – a growth of 16.36%. In the next year, analysts believe that EBITDA will reach $13.15B – an increase of 25.66%. For the next seven years, the forecast is for EBITDA to grow by 28.90%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAYN Stock Forecast | Bayer | Hold |
5
|
26.90€ | Buy/Sell | 45.15€ | 11.52% |
| CAH Stock Forecast | Cardinal Health Inc | Hold |
13
|
$103.81 | Buy/Sell | $108.07 | 10.30% |
| CHD Stock Forecast | Church & Dwight Co Inc | Hold |
11
|
$107.25 | Buy/Sell | $96.90 | -1.45% |
Abbott Laboratories EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's EBIT has grown by 27.45%, rising from $5.67B to $7.22B. For the next year, analysts predict that EBIT will reach $11.31B – an increase of 56.67%. Over the next seven years, experts believe that Abbott Laboratories's EBIT will grow at a rate of 137.85%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 7751 Stock Forecast | Canon | Hold |
18
|
¥4.28k | Buy/Sell | ¥3.74k | -11.24% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$40.23 | Buy/Sell | $44.86 | 11.86% |
| ABMD Stock Forecast | Abiomed | - |
16
|
$377.79 | Buy/Sell | $380.00 | -88.33% |
Abbott Laboratories EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Abbott Laboratories's EPS has decreased from $3.65 to $0.00 – a 100.00% drop. For next year, analysts predict EPS of $5.53, which would mean an increase of 100.00%. Over the next seven years, experts predict that Abbott Laboratories's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.46k | Buy/Sell | ¥2.64k | 39.18% |
| CIPLA Stock Forecast | Cipla | Outperform |
18
|
Rp1.41k | Buy/Sell | Rp1.43k | 6.56% |
| BIM Stock Forecast | bioMérieux | Outperform |
18
|
99.50€ | Buy/Sell | 105.55€ | 14.32% |
.jpg)